Sampo plc
14.1.2026 07:30:00 CET | Globenewswire | Press release
Sampo plc’s share buybacks 13 January 2026
Sampo plc’s share buybacks 13 January 2026
Sampo plc, stock exchange release, 14 January 2026 at 8:30 am EET
Sampo plc’s share buybacks 13 January 2026
On 13 January 2026, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:
| Sampo plc’s share buybacks | Aggregated daily volume (in number of shares) | Daily weighted average price of the purchased shares* | Market (MIC Code) |
| 5,737 | 9.85 | AQEU | |
| 155,632 | 9.87 | CEUX | |
| 38,628 | 9.87 | TQEX | |
| 202,380 | 9.87 | XHEL | |
| TOTAL | 402,377 | 9.87 |
* rounded to two decimals
On 5 November 2025, Sampo announced a share buyback programme of up to a maximum of EUR 150 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 6 November 2025, is based on the authorisation granted by Sampo's Annual General Meeting on 23 April 2025.
After the disclosed transactions, the company owns in total 11,303,152 Sampo A shares representing 0.42 per cent of the total number of shares in Sampo plc.
Details of each transaction are included as an appendix of this announcement.
On behalf of Sampo plc,
Morgan Stanley
For further information, please contact:
Sami Taipalus
Head of Investor Relations
tel. +358 10 516 0030
Distribution:
Nasdaq Helsinki
Nasdaq Stockholm
Nasdaq Copenhagen
London Stock Exchange
FIN-FSA
The principal media
www.sampo.com
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Shufti Pro Limited19.8.2026 16:00:00 CEST | Press release
Shufti Helps Obliged Entities Get Ready for the EU AMLR Ahead of the July 2027 Deadline
Cosmos Health Inc.19.8.2026 15:00:00 CEST | Press release
Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway
Teva Pharmaceutical Industries Ltd19.8.2026 14:30:00 CEST | Press release
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
Exclaimer Ltd.19.8.2026 14:00:00 CEST | Press release
Exclaimer Launches MSP Connect to Remove Billing and Management Friction for MSPs
Aduro Clean Technologies Inc.19.8.2026 14:00:00 CEST | Press release
Aduro Selects Saipem for Engineering and Procurement Support for First-of-a-Kind HCT Facility at Chemelot
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom